Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Parasite
    (9)
  • SARS-CoV
    (3)
  • HIV Protease
    (2)
  • Others
    (7)
Filter
Search Result
Results for "

w2 p. falciparum

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    10
    TargetMol | Inhibitors_Agonists
SARS-CoV-IN-1
T12837888958-25-6
SARS-CoV-IN-1 is an effective SARS-CoV replication inhibitor with an EC50 of 4.9 μM in Vero cells.
  • $1,780
6-8 weeks
Size
QTY
SARS-CoV-IN-2
T12838888958-26-7
SARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication.
  • $1,780
6-8 weeks
Size
QTY
SARS-CoV-IN-3
T12839888958-27-8
SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication.
  • $1,780
6-8 weeks
Size
QTY
Arterolane
RBx 11160, OZ 277
T14325664338-39-0
Arterolane is an antimalarial compound. For against P. falciparum Ro73 and W2, the IC50s are both 1.1 nM.
  • $347
10-14 weeks
Size
QTY
Antiparasitic agent-22
T209857
Antiparasitic agent-22 (Compound 24) is a broad-spectrum antiparasitic compound that inhibits the procyclic form of T. brucei, L. infantum, and L. tropica with IC50 values of 2.41, 5.95, and 8.98 μM, respectively, and the amastigote form of L. infantum with an IC50 of 8.18 μM. It also shows inhibitory activity against the P. falciparum W2 strain with an IC50 of 0.155 μM. Additionally, Antiparasitic agent-22 exhibits low cytotoxicity in THP1 cells, with a CC50 of 64.16 μM.
    Inquiry
    Keenamide A
    T32372177742-52-8
    Keenamide A, a cytotoxic cyclic hexapeptide, exhibits significant activity towards the P-388, A-549, MEL-20, and HT-29 tumor cell lines, but was inactive against the D6 and W2 Plasmodium falciparum malarial clones.
    • Inquiry Price
    Size
    QTY
    AN3661
    T366491268335-33-6
    AN3661, a potent antimalarial lead compound, targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue subunit 3 (PfCPSF3) and inhibits Plasmodium falciparum laboratory-adapted strains, Ugandan field isolates, and murine P. berghei and P. falciparum infections[1].
      7-10 days
      Inquiry
      Purfalcamine
      T382691038620-68-6
      Purfalcamine is an orally active, selective Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) inhibitor with an IC50 of 17 nM and an EC50 of 230 nM, exhibiting antimalarial activity by inducing developmental arrest of malaria parasites at the schizont stage[1][2].
      • $1,520
      6-8 weeks
      Size
      QTY
      Antimalarial agent 24
      T789512299199-54-3
      Compound 24 (Compound 7), an in vitro antimalarial agent, demonstrates inhibitory activity against the Plasmodium falciparum W2 strain with an IC50 of 0.81 μM and exhibits a cytotoxicity threshold (CC50) exceeding 200 μM in HepG2 cells [1].
      • $1,520
      6-8 weeks
      Size
      QTY
      5-(3-bromo-4,5-dihydroisoxazol-5-yl)-3-(4-(tert-butyl)phenyl)-1,2,4-oxadiazole
      T98582863687-18-5
      Antileishmanial agent-2 is a 3-Br-isoxazoline-Based Inhibitors against Plasmodium falciparum (D10 and W2 strains) and Leishmania spp. (L. infantum and L. tropica) Promastigotes with IC50s of 0.035, 0.058, 3.5 and 7.5 μM.
      • $70
      In Stock
      Size
      QTY